Randomized noninferiority trial demonstrates noninferior cardiovascular safety of testosterone-replacement therapy in men with hypogonadism, indicating comparable risk to placebo.
In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events. (Funded by AbbVie and others; TRAVERSE ClinicalTrials.gov number, NCT03518034.).
No takes yet. Share an insight, caveat, or question.
Lincoff et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: